Cell X Technologies and BioLamina Partner on induced pluripotent stem cell (iPSC) Standardization
The collaboration aims to streamline iPSC manufacturing by combining automation with standardized reagents for reproducible, scalable cell therapy processes.
Cell X Technologies has announced a collaboration with BioLamina to integrate BioLamina’s defined laminin reagents (Biolaminin®) with the Cell X Celligent™ platform. The goal is to reduce variability and improve reproducibility in advanced therapy manufacturing.
The partnership focuses on combining automation with standardized, high-quality reagents to support scalable and GMP-compliant (Good Manufacturing Practice) workflows for next-generation therapies. By using BioLamina’s full-length, human recombinant laminin-521 and laminin-511 isoforms—including both research-use-only and GMP-compatible versions—within automated workflows, the two companies aim to streamline iPSC (induced pluripotent stem cell) culture and differentiation, while reducing operator-dependent variability.
Lynne Frick, CEO of Cell X Technologies, stated: “Cell X Technologies is committed to advancing automation in regenerative medicine by ensuring that best-in-class reagents are seamlessly integrated into our automated workflows for process characterization, development and manufacturing. Our collaboration with BioLamina reflects a shared vision of reducing variability and increasing successes, especially during the critical transition from research to clinical application.”
Klaus Langhoff-Roos, CEO of BioLamina, commented: “Standardization, reproducibility, and physiological relevance are at the core of BioLamina’s mission to improve patient outcomes and save lives. Partnering with Cell X Technologies enables us to showcase how full-length equals full-function. This, when combined with advanced automation platforms, can drive predictable consistency and scalability for iPSC-based manufacturing.”
According to the companies, this combination is intended to support robust, reproducible, and regulator-ready cell therapy processes, facilitating reliable therapeutic development and manufacturing in regenerative medicine.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
